Patents by Inventor Xiang-Ju Justin GU

Xiang-Ju Justin GU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Triazolopyrimidine compounds and uses thereof
    Patent number: 11931363
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Grant
    Filed: October 19, 2021
    Date of Patent: March 19, 2024
    Assignee: NOVARTIS AG
    Inventors: Ho Man Chan, Xiang-Ju Justin Gu, Ying Huang, Ling Li, Yuan Mi, Wei Qi, Martin Sendzik, Yongfeng Sun, Long Wang, Zhengtian Yu, Hailong Zhang, Ji Yue (Jeff) Zhang, Man Zhang, Qiong Zhang, Kehao Zhao
  • QUINOLINE COMPOUNDS AND COMPOSITIONS FOR INHIBITING EZH2
    Publication number: 20230167100
    Abstract: The invention disclosed herein relates to aza-quinoline compounds of Formula (I), pharmaceutical compositions comprising such compounds, and the use of such compounds for treating a disease or condition mediated by Enhancer of Zeste Homolog 2 (EZH2), Polycomb Repressive Complex 2 (PRC2), or a combination thereof.
    Type: Application
    Filed: August 10, 2021
    Publication date: June 1, 2023
    Inventors: Xuan DAI, Michael DORE, Xiang-Ju Justin GU, Ling LI, Kun Chin LIU, Sing Yeung Frankie MAK, Yuan MI, Counde OYANG, Julien PAPILLON, Wei (Vicky) QI, Xiaoxia YAN, Zhengtian YU, Ji Yue (Jeff) ZHANG, Kehao ZHAO
  • TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20230033320
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Application
    Filed: October 19, 2021
    Publication date: February 2, 2023
    Inventors: Ho Man CHAN, Xiang-Ju Justin GU, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue (Jeff) ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • AZA-QUINOLINE COMPOUNDS AND USES THEREOF
    Publication number: 20220280509
    Abstract: Provided aza-quinoline compounds of Formula (I), pharmaceutical compositions comprising such compounds; and the use of such compounds for treating a disease or condition mediate by Enhancer of Zeste Homolog 2 (EZH2), Polycomb Repressive Complex 2 (PRC2), or a combination thereof.
    Type: Application
    Filed: September 24, 2020
    Publication date: September 8, 2022
    Inventors: Ling LI, Xuan DAI, Michael DORE, Xiang-Ju Justin GU, Kevin Kun Chin LIU, Sing Yeung Frankie MAK, Yuan MI, Counde OYANG, Julien PAPILLON, Wei (Vicky) QI, Xiaoxia YAN, Zhengtian YU, Ji Yue (Jeff) ZHANG, Kehao ZHAO
  • Triazolopyrimidine compounds and uses thereof
    Patent number: 11207325
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: December 28, 2021
    Assignee: Novartis AG
    Inventors: Ho Man Chan, Xiang-Ju Justin Gu, Ying Huang, Ling Li, Yuan Mi, Wei Qi, Martin Sendzik, Yongfeng Sun, Long Wang, Zhengtian Yu, Hailong Zhang, Ji Yue (Jeff) Zhang, Man Zhang, Qiong Zhang, Kehao Zhao
  • TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20200323859
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Application
    Filed: April 30, 2020
    Publication date: October 15, 2020
    Inventors: Ho Man CHAN, Xiang-Ju Justin GU, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue (Jeff) ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • Triazolopyridine compounds and uses thereof
    Patent number: 10689378
    Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R6, R7 and R8 are as defined herein.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: June 23, 2020
    Assignee: Novartis AG
    Inventors: Ho Man Chan, Xingnian Fu, Xiang-Ju Justin Gu, Ying Huang, Ling Li, Yuan Mi, Wei Qi, Martin Sendzik, Yongfeng Sun, Long Wang, Zhengtian Yu, Hailong Zhang, Ji Yue Zhang, Man Zhang, Qiong Zhang, Kehao Zhao
  • Imidazolepyridine compounds and uses thereof
    Patent number: 10676479
    Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: June 9, 2020
    Assignee: Novartis AG
    Inventors: Ho Man Chan, Xingnian Fu, Xiang-Ju Justin Gu, Ying Huang, Ling Li, Yuan Mi, Wei Qi, Martin Sendzik, Yongfeng Sun, Long Wang, Zhengtian Yu, Hailong Zhang, Ji Yue Zhang, Man Zhang, Qiong Zhang, Kehao Zhao
  • IMIDAZOLEPYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20190233426
    Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R3, R4, R6, and R7 are as defined herein.
    Type: Application
    Filed: June 9, 2017
    Publication date: August 1, 2019
    Inventors: Ho Man CHAN, Xingnian Fu, Xiang-Ju Justin Gu, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • TRIAZOLOPYRIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20190202828
    Abstract: A compound of Formula (IA), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein A, R6, R7 and R8 are as defined herein.
    Type: Application
    Filed: June 6, 2017
    Publication date: July 4, 2019
    Inventors: Ho Man CHAN, Xingnian Fu, Xiang-Ju Justin Gu, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20190142837
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Application
    Filed: January 11, 2019
    Publication date: May 16, 2019
    Inventors: Ho Man CHAN, Xiang-Ju Justin GU, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue (Jeff) ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • Triazolopyrimidine compounds and uses thereof
    Patent number: 10220036
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: March 5, 2019
    Assignee: Novartis AG
    Inventors: Ho Man Chan, Xiang-Ju Justin Gu, Ying Huang, Ling Li, Yuan Mi, Wei Qi, Martin Sendzik, Yongfeng Sun, Long Wang, Zhengtian Yu, Hailong Zhang, Ji Yue (Jeff) Zhang, Man Zhang, Qiong Zhang, Kehao Zhao
  • TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20170348312
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Application
    Filed: December 21, 2015
    Publication date: December 7, 2017
    Inventors: Ho Man CHAN, Xiang-Ju Justin GU, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue (Jeff) ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO
  • Triazolopyrimidine compounds and uses thereof
    Patent number: 9580437
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: February 28, 2017
    Assignee: Novartis AG
    Inventors: Ho Man Chan, Xiang-Ju Justin Gu, Ying Huang, Ling Li, Yuan Mi, Wei Qi, Martin Sendzik, Yongfeng Sun, Long Wang, Zhengtian Yu, Hailong Zhang, Ji Yue (Jeff) Zhang, Man Zhang, Qiong Zhang, Kehao Zhao
  • TRIAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF
    Publication number: 20160176882
    Abstract: A compound of Formula (I), or a pharmaceutically acceptable salt thereof, is provided that has been shown to be useful for treating a PRC2-mediated disease or disorder: wherein R1, R2, R3, R4, R5, and n are as defined herein.
    Type: Application
    Filed: December 21, 2015
    Publication date: June 23, 2016
    Inventors: Ho Man CHAN, Xiang-Ju Justin GU, Ying HUANG, Ling LI, Yuan MI, Wei QI, Martin SENDZIK, Yongfeng SUN, Long WANG, Zhengtian YU, Hailong ZHANG, Ji Yue (Jeff) ZHANG, Man ZHANG, Qiong ZHANG, Kehao ZHAO